YOLFTbeta
30

PeopleBio Inc

304840 · KQ · Healthcare / Healthcare Equipment & Supplies

-

Price History

Full chart

Market Stats

52-Week Range561.00 – 2,245.00
Market Cap14.05B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.90
50-Day Avg561.00
200-Day Avg836.60

About

PeopleBio, Inc., a biotech company, engages in developing diagnostics for protein misfolding diseases worldwide. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases. The company has strategic collaborations with Seoul National University Bundang Hospital, Etablissement Français du Sang, ADNI Private Partner Scientific Board, Eisai Co., Ltd., Macrogen Corp., ZheJiang Dian Diagnostics Co., Ltd., and LabGenomics, Inc. PeopleBio, Inc. was founded in 2002 and is based in Seongnam, South Korea.

Company Details

  • SectorHealthcare
  • IndustryHealthcare Equipment & Supplies
  • CEOMr. Sungmin Kang
  • Employees0
  • Headquarters242 Pangyo-ro, Seongnam-si, South Korea, 13487, Korea
  • Websitehttp://www.peoplebio.net

Leadership

  • Mr. Sungmin KangChief Exec. Officer and Pres · b. 1972

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue051.29M895.04M507.85M577.08M4.44B4.45B3.73B2.85B
Growth (%)--+1645.14%-43.26%+13.63%+670.22%+0.18%-16.20%-23.61%
Cost of Revenue098.32M593.83M647.52M1.35B3.09B3.05B2.38B3.32B
Gross Profit0-47.03M301.21M-139.67M-771.49M1.36B1.40B1.35B-464.47M
Gross Margin--91.71%33.65%-27.50%-133.69%30.51%31.54%36.22%-16.29%
Operating Expense2.01B3.72B4.39B4.42B6.46B13.05B17.68B12.93B7.85B
Operating Income-2.01B-3.77B-4.09B-4.56B-7.23B-11.69B-16.27B-11.58B-8.31B
Operating Margin--7347.05%-456.73%-897.03%-1253.56%-263.08%-365.44%-310.42%-291.66%
EBITDA------10.74B-13.42B-6.53B-8.10B
EBITDA Margin------241.68%-301.35%-174.96%-284.13%
Net Income-4.24B-3.55B-4.00B-4.38B-4.70B-14.31B-16.03B-10.91B-15.71B
Net Income Margin--6912.77%-447.04%-863.09%-814.96%-321.84%-359.99%-292.32%-551.26%
R&D---1.89B2.12B3.39B5.16B3.46B1.75B
R&D as % of Total Revenue---372.35%367.20%76.26%115.89%92.65%61.40%
Interest Expense00024.83M1.13B2.98B2.40B1.07B2.70B
Interest Expense % of Total Revenue-0.00%0.00%4.89%196.50%67.01%53.88%28.67%94.70%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.38B6.52B4.36B10.65B51.35B42.32B27.58B27.07B44.57B
Total Liabilities670.98M1.11B1.66B1.83B34.43B38.24B8.41B18.68B15.95B
Total Equity1.71B5.41B2.70B8.83B16.92B4.08B19.17B8.39B28.62B
Cash301.15M59.79M192.94M6.26B38.81B13.64B691.18M1.26B80.10M
Total Debt--172.89M70.95M-----
Net Debt-----1.34B643.36M7.29B7.30B

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.78B-2.43B-2.65B-3.49B-6.83B-13.97B-16.28B-10.91B-5.18B
Investing Cash Flow1.72B-4.31B2.96B-449.90M-3.97B-11.54B1.32B-674.20M-
Financing Cash Flow154.50M6.50B-169.66M10.01B43.35B350.08M2.01B12.16B-
Capital Expenditure10.77M28.85M1.90M157.99M1.35B1.34B760.23M114.74M323.78M
Free Cash Flow---2.58B-3.70B-8.22B-15.31B-17.04B-11.03B-5.51B
FCF to OCF--97.46%105.88%120.34%109.59%104.67%101.05%106.25%

Earnings

Report DateJun 9, 2021Jun 30, 2021Sep 30, 2021Mar 18, 2022Jun 7, 2022Jun 30, 2022Nov 29, 2022Dec 31, 2022May 15, 2023Aug 14, 2023Nov 14, 2023Mar 21, 2024May 16, 2024Aug 14, 2024Nov 12, 2024Mar 19, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 18, 2026May 13, 2026Jun 30, 2026
EPS Estimate----------------------
EPS Actual-116.07-174.41-163.10141.36-211.8934.91-231.92-627.34-409.85-245.37-253.39-152.36-145.68-137.67-141.16-79.81-131.83-67.74-51.54-484.15-92.50-95.50
Surprise----------------------
Timing---Pre-marketPre-market-After-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap14.05B
Enterprise Value90.23B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.30
Price / Book0.49
Revenue (TTM)3.69B
Gross Profit (TTM)-787.66M
EBITDA-7.11B
Profit Margin-94.71%
Operating Margin-226.81%
Return on Equity-10160.55%
Return on Assets-10.96%
Shares Outstanding0
Shares Float9.43M
Beta0.90
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%